bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

In the latest trading session, Bluebird Bio (BLUE) closed at $91.77, marking a +1.75% move from the previous day.

Bluebird Bio (BLUE) Outpaces Stock Market Gains: What You Should Know

Amicus Therapeutics

Global Blood Therapeutics

Intercept Pharma

uniQure

5 Best Mid-Cap Biotech Acquisition Targets

Bristol-Myers

Forty Seven Inc

Johnson & Johnson

The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.

The Top Biotech Stocks to Watch Following ASH 2019

bluebird (BLUE) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

bluebird (BLUE) Catches Eye: Stock Jumps 6.8%

bluebird bio (NASDAQ:BLUE) and its partner Bristol-Myers Squibb (NYSE:BMY) announced positive results from several studies using its LentiGlobin gene therapy to treat patients with beta-thalassemia.

bluebird bio's Advancement With Zynteglo Gene Therapy Is Properly Set Up For Commercial Success

argenx

Blueprint Medicines

Epizyme

Fate Therapeutics

Magenta Therapeutics Inc

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Wedbush’s Top Picks After ASH Annual Meeting

Bluebird Bio is continuing a steady march toward becoming a fully commercial biotech company in 2020, an analyst said Wednesday as he raised his price target on Bluebird Bio stock.

Will This Biotech Company Soon Nab Another Gene Therapy Approval?

Solid data from the biggest blood disease meeting of the year has the biotech flying high.

Here’s Why bluebird bio Shares Jumped Almost 12% Today

bluebird (BLUE) and partner Bristol-Myers report positive top-line results from a phase II study on idecabtagene vicleucel in patients with relapsed and refractory multiple myeloma.

bluebird Reports Positive Top-Line Data on Myeloma Drug

Chewy

Stitch Fix

Shopify

Toll Brothers

Chewy, Toll Brothers, Stitch Fix, bluebird bio and Shopify were our top stock trades from Monday. Here's a look at the charts.

5 Top Stock Trades for Tuesday: CHWY, SFIX, SHOP, TOL & BLUE

Investors need to pay close attention to bluebird (BLUE) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in bluebird (BLUE) Stock?

On a day that the Dow Jones industrials and S&P 500 just hit all-time highs, many companies are not exactly feeling the same love as the market darlings that took the indexes up so much.

After a 50% Drop, One Analyst Sees Bluebird Bio With Almost 50% Upside

Exact Sciences

These drug stocks are among the best to buy now because each is making progress in the fight against cancer. Here's what you should know about each.

3 Cancer-Fighting Drug Stocks to Buy Right Now

bluebird bio recently presented impressive Phase II/III data from their Lenti-D program from cerebral adrenoleukodystrophy (CALD).

bluebird bio: Market Fails To React To Impressive Data On Lenti-D Gene Therapy For CALD

Wall Street has soured on the company's prospects as it eyes a transition to commercial operations.

Here's Why bluebird bio Fell 21.3% in August

Bluebird (BLUE) reported earnings 30 days ago. What's next for the stock?

Bluebird (BLUE) Down 19.4% Since Last Earnings Report: Can It Rebound?

Bluebird Bio is growing its nest in Seattle.

Gov. Inslee helps Bluebird Bio open new ‘nest’ for cancer research efforts in Seattle

Bluebird Bio stock dipped Monday after an analyst suggested the biotech company's gene therapy, Zynteglo, would be a slow mover. Zynteglo treats transfusion-dependent beta thalassemia.

Why This Biotech's $1.8 Million Gene Therapy Could Be A 'Slow Mover'

Zynteglo was recently approved in Europe.

bluebird bio Prepares for Launch

bluebird (BLUE) posts wider-than-expected loss, while sales beat estimates in the second quarter of 2019.

bluebird's (BLUE) Loss Wider Than Expected, Revenues Beat

Atara Biotherapeutics

Genprex

Hemispherx Biopharma

Incyte

As our understanding of how cancer works evolves, so too are the methods that we are taking to treat the condition.

5 Immunotherapy Stocks to Keep a Close Eye On

Will this bluebird ever bring happiness to its shareholders?

Is bluebird bio (BLUE) a Buy?

bluebird bio's gene therapy, Zynteglo, gets the thumbs up on a conditional approval to treat patients with ß-thalassemia in the EU. However, it appears the company will have to wait.

bluebird bio: Returning To A Previous Winner

Bluebird Bio stock dipped Tuesday after an analyst noted manufacturing hiccups will prevent the biotech company from selling its gene therapy in Europe and the U.S. until 2020 and 2021, respectively.

Why This Biotech's Approved Gene Therapy Won't Launch Until 2020

Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.

News for bluebird bio Stock (BLUE)